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Aims Peripheral arterial disease (PAD) is highly prevalent in general population. Data on the prevalence of symptomatic PAD
in patients with atrial fibrillation (AF) are limited, and the impact of PAD on adverse outcomes in AF patients is con-
troversial. Our aims were: (i) to define the prevalence of symptomatic PAD in European AF patients and describe its
associated clinical risk factors and (ii) to establish the relationship of PAD to adverse events in AF, especially all-cause
death.
Methods Atrial fibrillation patients enrolled in the EORP-AF Pilot study with data about PAD status were included in this analysis.
Event rates were determined at 1-year follow-up.
Results Peripheral arterial disease was recorded in 328 (11%) patients. Age (P, 0.0001), hypertension (P ¼ 0.0059), diabetes
mellitus (P ¼ 0.0001), chronic heart failure (P, 0.0001), previous stroke/transient ischaemic attack (P ¼ 0.0060), and
antiplatelet drug treatment (P ¼ 0.0001) were associated with the presence of PAD, while female gender was inversely
associated (P ¼ 0.0002). Peripheral arterial disease patients had higher absolute rates of both cardiovascular (CV) and
all-cause death (both P, 0.0001). On Kaplan–Meier analysis, risk of all-cause death was higher in PAD patients com-
pared with those without PAD (P, 0.0001), but PAD did not emerge as an independent risk factor for mortality on
Cox regression analysis. A lower risk of all-cause death was associated with the prescription of statins (P ¼ 0.0019),
angiotensin-converting enzyme inhibitors (P ¼ 0.0008), and calcium-channel blockers (P ¼ 0.0071).
Conclusion Peripheral arterial disease is prevalent in 11% of AF patients and related to various atherosclerotic risk factors. Even if
PAD is associated with higher risk of all-cause death on univariate analysis, this risk was significantly lowered and was no
longer evident after adjusting for the use of CV prevention drugs.
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Introduction
Peripheral arterial disease (PAD) is a highly prevalent cardiovascular
(CV) condition,1,2 with a prevalence of 8.3%,3 being higher in males
and increasing with age.3 Being frequently asymptomatic, PAD is
quite often underestimated and underdiagnosed.2,4 The use of the
ankle-brachial index to identify patients with asymptomatic PAD
has been recommended.4,5
Peripheral arterial disease is an important independent risk factor
for total mortality and incident CV events in the general popula-
tion.2 Large cohort studies have shown that PAD prevalence among
AF patients is higher compared with non-AF subjects.6,8 Moreover,
the concomitant presence of AF and PAD confers a higher risk for
both atherosclerotic and thromboembolic adverse events, when
compared with that of AF without PAD.6,9 Hence, PAD is part of
the CHA2DS2-VASc score, which is used to assess thromboembolic
risk in AF patients.10 However, data on the impact of PAD on all-
cause death in patients with AF have been controversial.9 Nonethe-
less, several studies have shown that AF patients have a higher risk
for atherosclerosis-related major adverse events11 – 13 beyond
thromboembolic risk, underlining how the links between AF and
atherosclerosis may be even stronger than the mere epidemiologic-
al association.14
Data on the prevalence of PAD in AF have been reported with
percentages ranging from 4 to 17%, according to the different clin-
ical settings and definitions used.15 Recent data from a large ‘real
world’ Italian observational study of PAD prevalence in non-valvular
AF patients showed a high prevalence of asymptomatic PAD
(21%),16 with a higher risk of vascular events in those AF patients
with concomitant PAD diagnosis compared with those without
PAD.13 In contrast, an ancillary analysis from the ‘Rivaroxaban
Once daily, oral, direct factor Xa inhibition Compared with vitamin
K antagonism for prevention of stroke and Embolism Trial in Atrial
Fibrillation’ (ROCKET-AF) study documented a lower prevalence
(5.9%) of symptomatic PAD in this highly selected clinical trial
population.17
The EURObservational Research Programme Atrial Fibrillation
(EORP-AF) Pilot General Registry is a prospective multi-national
survey conducted by the European Society of Cardiology in nine
European countries to determine clinical features, treatment
patterns, and outcomes among patients with AF managed by
cardiologists.18 The objectives of this study were: (i) to assess the
prevalence of symptomatic PAD among European AF patients
seen by cardiologists, (ii) to establish clinical factors associated
with the presence of PAD, (iii) to evaluate adverse events associated
with PAD at 1-year follow-up, and (iv) to determine the impact of
PAD on all-cause mortality in AF patients at 1-year follow-up, as
well as the influence of CV prevention drug treatments.
Methods
Details on the EORP-AF study design, baseline, and 1-year prospective
results have been previously described.18,19 Briefly, EORP-AF was a pro-
spective registry of consecutive AF patients managed by cardiologists,
conducted by the European Society of Cardiology in the following
European countries: Belgium, Denmark, Netherlands, Norway, Poland,
Romania, Greece, Italy, and Portugal. Institutional review board for
every institution approved the study protocol. All patients entered
the study after signing a written informed consent. The study was
performed according to the EU Note for Guidance on Good Clinical
Practice CPMP/ECH/135/95 and the Declaration of Helsinki.
The study enrolled both in- and outpatients accessing to cardiology
services (either hospital- or office-based centres) with AF as a primary
or secondary diagnosis. The qualifying AF event was recorded by a
12-lead ECG, 24 h ECG Holter or other electrocardiographic docu-
mentation and should have been occurred within the 12 months before
the enrolment. Follow-up data were recorded 1 year after the enrol-
ment date according to the procedures previously described.13 From
February 2012 to March 2013, a total of 3119 AF patients were enrolled.
All patients with available data about PAD status were included in the
present analysis.
Peripheral arterial disease diagnosis was established by investigators
at site level. The presence of PAD was defined by a positive history of
any of the following: intermittent claudication, previous surgery, percu-
taneous intervention or thrombosis on abdominal or thoracic aorta, and
lower extremity vessels. This assessment was performed by any phys-
ician during the clinical assessment and/or by searching through medical
records, if available. Patients without positive clinical history of PAD
were assigned to the ‘non-PAD’ group. The presence or absence of
PAD was recorded in the electronic case report form of the registry,
reporting the presence or absence of PAD, but with no further details
on its clinical manifestations. Types of AF were defined as follows: (i)
first detected AF, paroxysmal AF, and persistent AF were categorized
as ‘Non-Chronic AF’; and (ii) long-standing persistent AF and permanent
AF were categorized ‘Chronic AF’.
Thromboembolic risk was defined according to the CHA2DS2-VASc
score.10 ‘Low-risk’ patients were defined as males with a CHA2DS2-
VASc 0 or females with a CHA2DS2-VASc equal to 1; ‘moderate-risk’ pa-
tients were defined as male patients with a CHA2DS2-VASc score 1; and
‘high risk’ was defined as CHA2DS2-VASc score ≥2.20 Bleeding risk was
assessed, as recommended by European Society of Cardiology guide-
lines,21 based on the HAS-BLED bleeding score.22
During the pre-specified 1-year follow-up period, the occurrence of
major adverse events was evaluated. Based on the study protocol,
events recorded were as follows: CV death, all-cause death, and any
thromboembolic event (TE) [defined as the occurrence of any stroke,
transient ischaemic attack (TIA), acute coronary syndrome, coronary
intervention, cardiac arrest, and peripheral or pulmonary embolism).
Statistical analysis
Continuous variables were reported as mean+ SD or as median and
interquartile range. Between-group comparisons were made using a
non-parametric test (Kruskal–Wallis test). Categorical variables were
reported as percentages. Between-group comparisons were made using
a x2 test or a Fisher’s exact test if any expected cell count was ,5. For
What’s new?
† In atrial fibrillation (AF), concomitant symptomatic peripheral
arterial disease (PAD) is frequently reported. Its presence is
associated with several common cardiovascular risk factors.
† The presence of PAD in AF patients is associated with a high-
er risk of all-cause death.
† Common cardiovascular prevention drugs are associated
with a decreased mortality rate in AF patients with PAD.
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categorical variables with more than two possible values, exact P-values
have been estimated according to the Monte Carlo method.
A regression analysis was performed to establish the clinical factors
significantly associated with the presence of PAD. All variables consid-
ered of clinical relevance underwent a univariate analysis and those
predictors with a level significance of P, 0.10 were inserted into a
forward multivariate logistic model. Kaplan–Meier analysis was used
to establish the relation of PAD to all-cause death and differences in
survival were analysed using the log-rank test.
Evaluation of factors significantly associated with all-cause death
used a Cox proportional hazards analysis. All demographic variables
underwent a univariate analysis. All variables with a P-value of ,0.10
for the association to all-cause death at the univariate analysis were in-
serted in the stepwise multivariate model along with PAD. Additional
stepwise models were then performed inserting in any model a specific
class of drugs with a known role in CV prevention (i.e. influencing
atherosclerosis progression and/or reducing CV events) such as antipla-
telets, statins, angiotensin-converting enzyme (ACE) inhibitors, and
calcium-channel blockers. A Hosmer and Lemeshow goodness-of-fit
test was used to verify that the models were optimal. A two-sided
P-value of ,0.05 was considered statistically significant. All analyses
were performed using SAS statistical software version 9.3 (SAS Institute,
Inc., Cary, NC, USA).
Results
Of the original EORP-AF cohort, data on PAD status were available
for 2975 patients (40.7% female) (Figure 1). Chronic AF was re-
corded in 650 (22.3%) patients. A high thromboembolic risk, with
CHA2DS2-VASc ≥2, was recorded in 82.2%, while a high risk for
bleeding (HAS-BLED ≥3) was documented in 14.5%. At baseline,
31.6% were treated at least with one antiplatelet drug, while anti-
coagulant therapy was used in 1764 (59.9%) AF patients. Overall,
1154 (39.3%) patients were treated with a statin at enrolment.
Peripheral arterial disease was recorded in 11% (n ¼ 328).
Clinical characteristics in patients with and without PAD are
summarized in Table 1. Patients with PAD were more frequently
male (P ¼ 0.0070) and older (P, 0.0001) compared with patients
without PAD. Peripheral arterial disease patients had a higher preva-
lence of hypertension, diabetes mellitus, hypercholesterolaemia,
prior stroke/TIA, ischaemic thromboembolic complications, coron-
ary artery disease or chronic heart failure (CHF), and chronic kidney
disease (all P, 0.0001). Prior bleeding events were more reported
in PAD patients (P ¼ 0.0006).
As expected, patients with PAD had higher CHA2DS2-VASc than
patients without PAD; a high thromboembolic risk was recorded in
98.2% (P, 0.0001). HAS-BLED score was higher in patients with
PAD (P, 0.0001).
Pharmacological therapies distribution
At enrolment, PAD patients were more commonly treated
with antiplatelet drugs, usually acetylsalicylic acid, than those
without (P, 0.0001). Similarly, clopidogrel (P ¼ 0.0007), ticlopi-
dine (P ¼ 0.0020), non-dihydropyridine (DHP) calcium-channel
blockers (P ¼ 0.0261), and statins (P ¼ 0.0001) were more used
in PAD patients.
After discharge, PAD patients were more frequently started on
an oral anticoagulant drug (P ¼ 0.0186), whether a vitamin K
antagonist (P ¼ 0.0069) or non-vitamin K antagonist oral anticoagu-
lant (P ¼ 0.009). Statin therapy use was higher at discharge in in
patients taking anticoagulants, more commonly among PAD
patients (P, 0.0001). A higher proportion of PAD patients were
treated with antiplatelet drugs (P, 0.0001), non-DHP calcium-
channel blockers (P ¼ 0.0064), and ACE inhibitors (P ¼ 0.0417).
Clinical determinants of peripheral
arterial disease
On the basis of the univariate logistic analysis (Supplementary
material online, Table S1), a multivariate model was constructed
(see Table 2). On multivariate logistic analysis, age (P, 0.0001),
hypertension (P ¼ 0.0059), diabetes mellitus (P ¼ 0.0001), CHF
(P, 0.0001), previous stroke/TIA (P ¼ 0.0060), and antiplatelet
therapy (P ¼ 0.0001) were significantly associated with the pres-
ence of PAD, while female gender (P ¼ 0.0002) was inversely asso-
ciated (Table 2). Of note, coronary artery disease was associated
with PAD on univariate but not multivariate analysis (Supplemen-
tary material online, Table S1).
Major adverse events and survival analysis
Follow-up data were available for a total of 2502 (84.1%) patients.
Of the whole cohort available at the pre-specified 1-year follow-up,
Patients enroled in the
original cohort
n = 3119
Patients without data
about PAD status
n = 144
Patients available for
present analysis
n = 2975
PAD patients
n = 328
PAD patients
availble for FU
n = 292
Non PAD patients
n = 2647
Non PAD patients
available for FU
n = 2210
Figure 1 Study patients’ flow chart.
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Table 1 Clinical characteristics of the population according to the presence of PAD
PAD (n 5 328) Non-PAD (n5 2647) P-value
Age (years)
N 328 2647
Mean+ SD 72.9+10.5 68.5+11.6 ,0.0001
Female gender 111/328 (33.8%) 1101/2647 (41.6%) 0.0070
Type of AF 0.1375
Non-chronic AF 242/325 (74.5%) 2022/2589 (78.1%)
Chronic AF 83/325 (25.5%) 567/2589 (21.9%)
Hypertension 270/326 (82.8%) 1820/2633 (69.1%) ,0.0001
Coronary artery disease 167/299 (55.9%) 795/2377 (33.4%) ,0.0001
Diabetes mellitus 112/325 (34.5%) 508/2634 (19.3%) ,0.0001
Hypercholesterolaemia 196/322 (60.9%) 1219/2586 (47.1%) ,0.0001
Current smoker 32/324 (9.9%) 287/2562 (11.2%) 0.4734
Previous stroke/TIA 51/316 (16.1%) 236/2632 (9.0%) ,0.0001
Chronic heart failure 225/325 (69.2%) 1147/2628 (43.6%) ,0.0001
LVEF (%)
N 257 2073
Median (IQR) 50.0 (39.0–60.0) 55.0 (45.0–60.0) 0.0001
Chronic kidney disease 91/325 (28.0%) 304/2642 (11.5%) ,0.0001
Bleeding events 33/317 (10.4%) 146/2639 (5.5%) 0.0006
Ischaemic thromboembolic complications 89/316 (28.2%) 302/2640 (11.4%) ,0.0001
CHA2DS2-VASc
N 328 2647
Median (IQR) 5.0 (4.0–6.0) 3.0 (2.0–4.0) ,0.0001
Low risk 0/328 (0.0%) 235/2647 (8.9%)
Intermediate risk 6/328 (1.8%) 287/2647 (10.8%)
High risk 322/328 (98.2%) 2125/2647 (80.3%)
HAS-BLED
N 328 2647
Median (IQR) 2.0 (1.0–3.0) 1.0 (1.0–2.0) ,0.0001
0–2 236/328 (72.0%) 2309/2647 (87.2%)
≥3 92/328 (28.0%) 338/2647 (12.8%)
Treatments before hospital admission/consultation
No antithrombotic agent 47/326 (14.4%) 579/2630 (22.0%) 0.0015
Any antiplatelet 151/326 (46.3%) 783/2630 (29.8%) ,0.0001
ASA 134/326 (41.1%) 728/2630 (27.7%) ,0.0001
Clopidogrel 29/325 (8.9%) 120/2634 (4.6%) 0.0007
Prasugrel (0.0%) (0.0%) NA
Ticagrelor (0.0%) 6/2634 (0.2%) .0.999a
Ticlopidine 7/326 (2.1%) 11/2633 (0.4%) 0.0020a
Indobufen 2/326 (0.6%) 4/2633 (0.2%) 0.1347a
Any anticoagulant 200/324 (61.7%) 1564/2623 (59.6%) 0.4665
Vitamin K Antagonists 184/324 (56.8%) 1397/2625 (53.2%) 0.2240
NOACs 8/326 (2.5%) 128/2634 (4.9%) 0.0504
Heparin 11/326 (3.4%) 57/2631 (2.2%) 0.1700
Other antithrombotic Agents (0.0%) 15/2633 (0.6%) 0.3970a
Statins 159/324 (49.1%) 995/2615 (38.0%) 0.0001
DHP calcium-channel blockers 51/324 (15.7%) 317/2619 (12.1%) 0.0619
Non-DHP calciumchannel blockers 24/324 (7.4%) 120/2619 (4.6%) 0.0261
ACE inhibitors 130/323 (40.2%) 990/2618 (37.8%) 0.3956
Treatments at discharge
No antithrombotic agent 4/328 (1.2%) 135/2641 (5.1%) 0.0016
Continued
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249 (10.0%) patients had a major adverse event (all-cause death +
any TE).
In the292 PAD patients, there were 53 (18.1%) major adverse
events, as summarized in the following: (i) 40 (13.7%) all-cause
deaths with 19 (6.5%) CV deaths and (ii) any TE in 13 (4.5%). In
the 2210 patients without PAD, 196 (8.9%) major adverse events
occurred as follows: all-cause death in 123 (5.6%), of which 49
(2.2%) were CV deaths, and ‘any TE’ in 73 (3.3%).
Figure 2, patients with PAD had higher rates of both CV and
all-cause death compared with patients without PAD (6.8 vs.
2.3% and 13.7 vs. 5.6%, respectively). When considering the
outcome of any TE, a non-significant numerical difference was
found between patients with and without PAD (6.0 vs. 3.7%)
(Figure 2).
On Kaplan–Meier survival analysis for all-cause death, patients
with PAD had a significantly higher risk for all-cause death than pa-
tients without PAD (P, 0.0001) (Figure 3).
On univariate Cox proportional hazards model analysis (Supple-
mentary material online, Table S2), clinical variables significantly as-
sociated with all-cause death were entered into the multivariable
Cox proportional hazards models (Table 3).
In Model 1, only clinical variables, age (,0.0001), diabetes melli-
tus (P ¼ 0.0005), CHF (P, 0.0001), chronic kidney disease (P,
0.0001), and the previous occurrence of haemorrhagic events
(P, 0.0009) were independently associated with the occurrence
of all-cause death, but PAD was not independently associated
with all-cause death (P ¼ 0.1096). In Model 2, which included
pharmacological therapy with any antiplatelet drug, the same clinical
variables were independently associated with all-cause death, but
therapy with any antiplatelet drug(s) was not independently asso-
ciated with all-cause death (P ¼ 0.2482).
Other multivariable models were compiled inserting one variable
at a time, successively, pharmacological therapy with statins in Model
3, ACE inhibitors in Model 4 and calcium-channel blockers in Model
5. These multivariable models showed that all-cause death was
independently inversely associated with statins (P ¼ 0.0019), ACE
inhibitors (P ¼ 0.0008), and DHP calcium-channel blockers (P ¼
0.0007). When considering all the drugs together in Model 6, results
of previous models were confirmed with statins (P ¼ 0.0111), ACE
inhibitors (P ¼ 0.0020), and DHP calcium-channel blockers (P ¼
0.0187) being all inversely associated with the occurrence of all-
cause death. Of note, coronary artery disease was significantly asso-
ciated with all-cause death on univariate but not multivariate
analysis.
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Table 1 Continued
PAD (n5 328) Non-PAD (n5 2647) P-value
Any antiplatelet 168/327 (51.4%) 878/2641 (33.2%) ,0.0001
ASA 149/327 (45.6%) 789/2641 (29.9%) ,0.0001
Clopidogrel 54/328 (16.5%) 250/2642 (9.5%) ,0.0001
Prasugrel 2/328 (0.6%) 2/2642 (0.1%) 0.0627a
Ticagrelor (0.0%) 6/2642 (0.2%) .0.999a
Ticlopidine 3/328 (0.9%) 6/2641 (0.2%) 0.0677a
Indobufen 3/328 (0.9%) 8/2641 (0.3%) 0.1128a
Any anticoagulant 284/328 (86.6%) 2144/2638 (81.3%) 0.0186
Vitamin K Antagonists 256/328 (78.0%) 1871/2638 (70.9%) 0.0069
NOACs 14/328 (4.3%) 222/2641 (8.4%) 0.0090
Heparin 27/328 (8.2%) 130/2641 (4.9%) 0.0115
Other antithrombotic Agents (0.0%) 10/2642 (0.4%) 0.6142a
Statins 198/328 (60.4%) 1276/2635 (48.4%) ,0.0001
DHP calcium-channel blockers 47/328 (14.3%) 342/2639 (13.0%) 0.4882
Non-DHP calcium-channel blockers 32/328 (9.8%) 155/2639 (5.9%) 0.0064
ACE inhibitors 159/328 (48.5%) 1123/2638 (42.6%) 0.0417
ACE, angiotensin-converting enzyme; AF, atrial fibrillation; ASA, acetylsalicylic acid; DHP, dihydropyridine; IQR, interquartile range; LVEF, left ventricular ejection fraction; NOACs,
non-vitamin K antagonists oral anticoagulants; SD, standard deviation; TIA, transient ischaemic attack.
aFisher’s exact test.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Multivariate logistic analysis for clinical
determinants of the presence of PAD at baseline
Odds ratio 95% CI P-value
Chronic heart failure 2.235 (1.725–2.896) ,0.0001
Hypertension 1.563 (1.138–2.148) 0.0059
Age (per years) 1.033 (1.020–1.045) ,0.0001
Diabetes mellitus 1.691 (1.295–2.208) 0.0001
Previous stroke/TIA 1.632 (1.151–2.314) 0.0060
Female gender 0.608 (0.468–0.791) 0.0002
Any antiplatelet 1.639 (1.277–2.102) 0.0001
ACE, angiotensin-converting enzyme; AF, atrial fibrillation; ASA, acetylsalicylic acid;
CI, confidence interval; DHP, dihydropyridine; IQR, interquartile range; LVEF, left
ventricular ejection fraction; NOACs, non-vitamin K antagonists oral
anticoagulants; TIA, transient ischaemic attack.
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Discussion
In this study, we show first that symptomatic PAD is prevalent in
11% of patients with AF; secondly, various clinical factors frequent-
ly associated with AF were also associated with the presence of
PAD; thirdly, patients with PAD had higher absolute rates of
both CV and all-cause death. Also, the incidence of any TE was nu-
merically higher in PAD patients than in those without. Finally, the
survival analysis for all-cause death showed that AF patients with
symptomatic PAD were at higher risk than patients without
PAD, but this was attenuated by CV drugs (statins, ACE inhibitors,
and calcium-channel blockers). However, PAD was not independ-
ently associated with all-cause death in AF patients, and neither
was coronary artery disease.
Reports on the prevalence of symptomatic PAD in AF patients
have been contradictory. In the Danish Diet, Cancer, and Health
study, 3.7% of AF patients were affected by PAD.23 Similarly, in
the ROCKET-AF trial, only 5.9% of patients had a diagnosis of
PAD at trial entry.17 The wide difference between those previous
reports and our data may reflect the nature of the study itself. In
studies based on ICD codes, as with the Danish ‘Diet, Cancer,
and Health’ study, reporting could be affected by wrong coding or
selection/sampling bias, while randomized controlled trials are a
highly selected cohort that may not reflect the ‘real world’ epidemi-
ology. Conversely, in an Italian large observational study, patients
with AF had a high prevalence (21%) of asymptomatic PAD.16
Among the clinical factors identified in our study as associated
with PAD, age, hypertension, and diabetes mellitus have been pre-
viously identified as risk factors both in general population2 and in
AF patients.16 Similarly, the majority of studies have highlighted high-
er prevalence rates in males than in females.2 The close association
with CHF and previous stroke/TIA, along with the higher propor-
tion of AF patients with a previous history of clinically evident
atherosclerotic disease among the PAD patients, underlines the
relationship between atherosclerotic vascular disease, AF, and CV
risk.
Moreover, the higher occurrence of both CV death and any TE in
AF patients with PAD reinforces the emerging concept that athero-
sclerotic vascular disease and AF may be more intimately related,
perhaps also from a pathophysiological perspective.14,24,25 This
has been supported by data from sub-analyses of studies showing
higher rates of CV events and death in patients with concomitant
AF and vascular disease (previous MI or PAD);9 as well as studies
showing that AF patients carry a higher risk of clinically relevant ath-
erosclerotic disease.13 Indeed, recent studies have shown that
AF patients are at higher risk of MI,13 in hospitalized patients,11
All-cause death P < 0.0001
P < 0.0001
P = 0.1093
CV death
Any TE
0% 1% 2% 3% 4% 5% 6% 7% 8% 9% 10% 11% 12% 13% 14% 15%
PAD Non-PAD
Figure 2 Major adverse event rates according to the presence of PAD. CV, cardiovascular; PAD, peripheral arterial disease; TE, thromboembol-
ic event.
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Table 3 Cox proportional hazards multivariable models for all-cause death
Hazard ratio 95% CI P-value
Model 1
Peripheral arterial disease 1.375 (0.931–2.030) 0.1096
Age (per years) 1.060 (1.041–1.080) ,0.0001
Diabetes mellitus 1.840 (1.308–2.589) 0.0005
Chronic heart failure 2.344 (1.583–3.471) ,0.0001
Chronic kidney disease 2.592 (1.820–3.691) ,0.0001
Haemorrhagic events 2.085 (1.350–3.220) 0.0009
Model 2
Peripheral arterial disease 1.406 (0.949–2.081) 0.0892
Age (per years) 1.066 (1.046–1.086) ,0.0001
Diabetes mellitus 1.886 (1.339–2.657) 0.0003
Chronic heart failure 2.347 (1.582–3.481) ,0.0001
Chronic kidney disease 2.608 (1.829–3.721) ,0.0001
Haemorrhagic events 2.067 (1.337–3.194) 0.0011
Any antiplatelet 0.818 (0.582–1.150) 0.2482
Model 3
Peripheral arterial disease 1.401 (0.947–2.072) 0.0916
Age (per years) 1.063 (1.044–1.083) ,0.0001
Diabetes mellitus 1.916 (1.359–2.702) 0.0002
Chronic heart failure 2.373 (1.598–3.525) ,0.0001
Chronic kidney disease 2.558 (1.788–3.658) ,0.0001
Haemorrhagic events 1.867 (1.198–2.909) 0.0058
Statins 0.584 (0.416–0.820) 0.0019
Model 4
Peripheral arterial disease 1.345 (0.907–1.994) 0.1408
Age (per years) 1.065 (1.045–1.085) ,0.0001
Diabetes mellitus 1.808 (1.281–2.551) 0.0008
Chronic heart failure 2.544 (1.706–3.794) ,0.0001
Chronic kidney disease 2.439 (1.705–3.490) ,0.0001
Haemorrhagic events 1.927 (1.243–2.987) 0.0034
ACE inhibitors 0.544 (0.381–0.776) 0.0008
Model 5
Peripheral arterial disease 1.330 (0.897–1.970) 0.1557
Age (per years) 1.065 (1.045–1.085) ,0.0001
Diabetes mellitus 1.925 (1.365–2.713) 0.0002
Chronic heart failure 2.243 (1.514–3.324) ,0.0001
Chronic kidney disease 2.670 (1.869–3.816) ,0.0001
Haemorrhagic events 2.008 (1.297–3.109) 0.0018
Calcium-channel blockers 0.394 (0.200–0.776) 0.0071
Model 6
Peripheral arterial disease 1.324 (0.888–1.974) 0.1685
Age (per years) 1.064 (1.044–1.084) ,0.0001
Diabetes mellitus 1.903 (1.345–2.693) 0.0003
Chronic heart failure 2.562 (1.712–3.833) ,0.0001
Chronic kidney disease 2.478 (1.722–3.566) ,0.0001
Haemorrhagic events 1.703 (1.089–2.664) 0.0196
Any antiplatelet 0.966 (0.679–1.374) 0.8489
Statins 0.635 (0.447–0.902) 0.0111
ACE inhibitors 0.570 (0.399–0.814) 0.0020
Calcium-channel blockers 0.442 (0.224–0.873) 0.0187
ACE, angiotensin-converting enzyme; CI, confidence interval. Hosmer and Lemeshow goodness-of-fit test for each model: P ¼ 0.5255.
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outpatients,26 or even in AF patients with low thromboembolic
risk.27 Sudden death is also increased in AF patients.1
When reviewing the relationship between AF, PAD, and all-cause
death, the available evidence seems conflicting. Various studies in-
volving PAD patients have documented a higher risk of all-cause
death in those patients with concomitant AF, but this risk was not
independent of other risk factors.6,28 In the ROCKET-AF study,
the absolute risk of all-cause death was higher in AF patients with
PAD, but there was a non-significant independent association of
PAD and all-cause death.17 The Diet, Cancer, and Health study
also found a significant association between PAD and all-cause death
in AF patients.23 In our study, the absolute rate of all-cause death
was significantly higher in PAD patients, but we did not find an inde-
pendent relationship from other clinical variables on multivariable
analysis.
Among the factors influencing the association between PAD and
all-cause death, our study shows that pharmacological therapy with
statins, ACE inhibitors, and calcium-channel blockers was inversely
associated with all-cause mortality. Conversely, the role of antipla-
telet therapies was inconclusive, being inversely associated with all-
cause death but not being statistically significant. Indeed, the
combined use of such pharmacological therapies in preventive CV
strategies seems effective in the general population and is currently
recommended by European guidelines for both general popula-
tion29 and PAD patients.30 Nonetheless, definitive data on CV risk
reduction for AF patients with concomitant symptomatic PAD are
lacking.
The role of statin therapy in lowering the incidence of CV events
and death in PAD patients among the general population, even if
never specifically tested in a properly designed study in this setting,
has largely been confirmed.31 For all-cause death, data from the
Reduction of Atherothrombosis for Continued Health (REACH)
registry showed that statin therapy in patients with PAD conferred
an almost 20% relative risk reduction.32 Conversely, a large
Cochrane systematic review on pharmacological therapy for PAD
documented inconclusive results of statins and all-cause death,
with a non-statistical significant inverse relationship with statins.33
Angiotensin-converting enzyme inhibitors in general PAD patients
may reduce CV events,34 but definitive data for ACE inhibitors in
modulating major adverse events in AF patients with PAD are
lacking.35
The calcium-channel blockers have previously been shown to be
effective in reducing CV events in general population.36 Indeed,
calcium-channel blockers may have an anti-atherosclerotic action.37
In particular, DHP calcium-channel blockers may slow the progres-
sion of coronary artery disease37,38 and downmodulate subclinical
atherosclerosis, both in animal models39 and in large randomized
clinical trials,40 independent of blood pressure reduction. Even if
specific data in PAD patients are not available, cross-sectional
data from the ‘Atrial Fibrillation Registry for Ankle-brachial Index
Prevalence Assessment: Collaborative Italian Study’ found an in-
verse association between calcium-channel blockers and subclinical
atherosclerosis25 in AF patients. Our data also suggest a potential
relevant role of calcium-channel blockers in PAD patients with AF.
It has largely been assumed that antiplatelet therapy is effective in
reducing CV events in this clinical setting,31 and thus in international
guidelines, aspirin is recommended as being effective in reducing
adverse events,30 given the data from the Antithrombotic Trialists’
Collaboration meta-analysis.41 However, recent meta-analyses
showed that the benefits of aspirin appear inconclusive,42 while
therapy with thienopyridines was perhaps more effective in redu-
cing major adverse events.43 Our study data seem to support this
evidence, with a non-significant association between antiplatelet
therapy (mainly aspirin) and all-cause death. Given their associated
comorbidities and concomitant risk factors, PAD patients need to
be managed in a holistic manner.31 The beneficial effects of pharma-
cological therapies seen in our study emphasize this concept even in
AF patients with concomitant PAD.
Limitations
EURObservational Research Programme Atrial Fibrillation was a
European cardiologist-based registry, so this could have led to an
overestimate of PAD prevalence. Conversely, this could have
resulted in enrolment of patients with more severe conditions
that could have reduced the influence of PAD on event rates. As
reported, asymptomatic PAD is a relevant issue in the assessment
of this condition. The lack of an objective assessment of PAD and
the absence of a more detailed description of the related clinical
status are major limitations to our study. Moreover, the relatively small
number of PAD patients, the short follow-up period, and missing
follow-up data in 16% of patients could have limited the influence
of PAD in determining all-cause death or thromboembolism. Finally,
EORP-AF was an observational study and was not adequately powered
to detect survival differences according to the presence of PAD; thus,
our data require confirmation from properly designed larger studies,
focused on patients with a well-defined PAD diagnosis.
Conclusions
In conclusion, PAD is prevalent in AF patients and related to various
atherosclerotic risk factors. Even if PAD is associated with higher
risk of all-cause death on univariate analysis, this risk was
significantly lowered and was no longer evident after adjusting for
the use of CV prevention drugs (statins, ACE inhibitors, and calcium-
channel blockers).
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Supplementary material is available at Europace online.
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